ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Vertex expands cystic fibrosis pact

by Lisa M. Jarvis
October 24, 2016 | APPEARED IN VOLUME 94, ISSUE 42

Vertex Pharmaceuticals and the drug discovery arm of the Cystic Fibrosis Foundation have expanded their research alliance. Vertex will get another $75 million up front and up to $6 million annually under the new pact. The partners have collaborated since 1998, with CFF contributing upward of $100 million to the company’s R&D prior to the approval of Kalydeco, the first disease-modifying cystic fibrosis treatment. In 2014, CFF sold its royalty rights to all of Vertex’s approved cystic fibrosis drugs for $3.3 billion.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment